ATEC

Business Context and Reporting Period

Company: Alphatec Holdings, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Industry: Medical Devices (Spine Fusion Products)
Overview: Alphatec designs, develops, manufactures, and markets spinal implant products and systems (screws, spacers, plates) primarily in the United States and Japan. The company operates as a holding company with no direct operations; its principal operating subsidiary is Alphatec Spine, Inc. The company went public in June 2006 via an IPO raising approximately $70.2 million in net proceeds.

Key Financial Metrics (Year Ended Dec 31, 2006)

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 74.8% to $74.0 million, driven by continued surgeon adoption, expansion of the U.S. distribution network, and organic growth in Japan.
• Margin Expansion: Gross margin improved by 7.2 percentage points to 65.3%, aided by the absence of a one-time inventory step-up charge incurred in 2005 and improved manufacturing operations.
• Expense Increases: Operating expenses rose significantly ($30.8 million increase) due to:
  • Sales & Marketing: Increased by $15.0 million due to higher commissions and headcount expansion.
  • General & Administrative: Increased by $16.2 million, largely due to a senior management reorganization ($6.5 million), legal fees, and the adoption of SFAS 123(R) requiring stock-based compensation expensing ($3.8 million).
  • Failed Acquisition Costs: $2.0 million recorded in 2006 related to the failed acquisition of Scient'x S.A.
• Liquidity: Cash position improved significantly from $2.2 million to $16.9 million following the June 2006 IPO.

Guidance, Outlook, Risks, and Contingencies

• Outlook: Management anticipates continued net losses for the foreseeable future as the company invests in sales force expansion, R&D, and new product commercialization. The company expects current cash and credit facilities to fund operations through 2007.
• Debt Covenants: As of December 31, 2006, Alphatec Spine was in breach of certain covenants under its Bank of the West credit facility. Waivers were obtained in November 2006 and March 2007, though interest rates were increased as a result.
• Legal Proceedings:
  • Patent Litigation: Biedermann Motech GmbH and Depuy Spine, Inc. sued Alphatec for patent infringement regarding the Zodiac and Solanas products. A preliminary injunction was denied, but the case remains pending with potential material impact if lost.
  • Royalty Dispute: Four surgeons sued for 6% royalties on polyaxial screw sales. The company intends to defend vigorously; the outcome is uncertain.
• Key Risks:
  • Concentration: Zodiac polyaxial pedicle screws represented 36.3% of 2006 net sales; these rely on a license from Biomet.
  • Supply Chain: Reliance on a single supplier (Invibio) for PEEK material and limited sources for allograft tissue.
  • Reimbursement: Dependence on third-party payors (Medicare/Medicaid) to reimburse hospitals for procedures using Alphatec products.
  • Internal Controls: A material weakness in internal controls was identified in 2005; while remediated in 2006, the company is not yet an accelerated filer subject to Section 404 of Sarbanes-Oxley.

Investor Verification Checklist

• Covenant Compliance: Verify the status of the Bank of the West credit facility covenants and the terms of the March 2007 amendment.
• Legal Exposure: Monitor the status of the Depuy/Biedermann patent infringement suit and the surgeon royalty dispute, as adverse outcomes could materially impact revenue.
• Product Concentration: Assess the risk associated with the Biomet license for polyaxial screws, which drive over one-third of revenue.
• Profitability Path: Review the trajectory of operating expenses relative to revenue growth to determine the timeline for achieving profitability.
• Supply Chain Resilience: Confirm the stability of the single-source PEEK supply agreement with Invibio.